203 related articles for article (PubMed ID: 29264517)
1. Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma.
Paepegaey AC; Lheure C; Ratour C; Lethielleux G; Clerc J; Bertherat J; Kramkimel N; Groussin L
J Endocr Soc; 2017 Jun; 1(6):646-649. PubMed ID: 29264517
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report.
Khatri S; Alom M; Kashfi S; Atallah J; Goswami G
J Investig Med High Impact Case Rep; 2023; 11():23247096231194401. PubMed ID: 37642143
[TBL] [Abstract][Full Text] [Related]
3. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
Hakami OA; Ioana J; Ahmad S; Tun TK; Sreenan S; McDermott JH
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836329
[TBL] [Abstract][Full Text] [Related]
4. Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient.
Spagnolo CC; Campo I; Campennì A; Cardile D; Cannavò S; Silvestris N; Santarpia M; Ruggeri RM
Hormones (Athens); 2024 Feb; ():. PubMed ID: 38421588
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
de Filette J; Jansen Y; Schreuer M; Everaert H; Velkeniers B; Neyns B; Bravenboer B
J Clin Endocrinol Metab; 2016 Nov; 101(11):4431-4439. PubMed ID: 27571185
[TBL] [Abstract][Full Text] [Related]
6. When Hormones are Being Difficult: A Rare Case and the Literature Review of Pembrolizumab-Induced Polyendocrinopathy.
Tayyeb M; Tariq M; Khan AM; Khalid F; Meghal T; Du D
J Community Hosp Intern Med Perspect; 2023; 13(6):90-94. PubMed ID: 38596553
[TBL] [Abstract][Full Text] [Related]
7. Adverse Endocrine-Related Effects of Pembrolizumab Precipitating Severe Hyponatremia.
Baldawi MB; Dhami B; Gosai J; Al-Khafaji RH
Cureus; 2022 Aug; 14(8):e28393. PubMed ID: 36171843
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab-Induced Thyroiditis.
Imblum BA; Baloch ZW; Fraker D; LiVolsi VA
Endocr Pathol; 2019 Jun; 30(2):163-167. PubMed ID: 31111437
[TBL] [Abstract][Full Text] [Related]
9. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
Ariyasu H; Inaba H; Ota T; Yamaoka H; Furukawa Y; Iwakura H; Doi N; Yamamoto Y; Akamizu T
In Vivo; 2018; 32(2):345-351. PubMed ID: 29475919
[TBL] [Abstract][Full Text] [Related]
10. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gallbladder With a Mass.
Fernandes NL; Sodavarapu S; Nedopil S; Mohapatra N; Vyas D
Cureus; 2020 Jun; 12(6):e8786. PubMed ID: 32724737
[TBL] [Abstract][Full Text] [Related]
12. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
13. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
[TBL] [Abstract][Full Text] [Related]
14. A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency.
Sonehara K; Tateishi K; Hirabayashi T; Araki T; Ikuyama Y; Machida R; Hanaoka M
Case Rep Oncol; 2021; 14(1):1-7. PubMed ID: 33613234
[TBL] [Abstract][Full Text] [Related]
15. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.
Cunha C; Silva E; Vieira AC; Saraiva C; Duarte S
Endocrinol Diabetes Metab Case Rep; 2022 Feb; 2022():. PubMed ID: 35140188
[TBL] [Abstract][Full Text] [Related]
16. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
[TBL] [Abstract][Full Text] [Related]
17. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
18. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
19. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
[TBL] [Abstract][Full Text] [Related]
20. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review.
Iglesias P; Sánchez JC; Díez JJ
Pituitary; 2021 Aug; 24(4):630-643. PubMed ID: 33761049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
